Integra LifeSciences (IART) Tops Q3 EPS by 11c, provides guidance

Integra LifeSciences (NASDAQ: IART) reported Q3 EPS of $0.54, $0.11 better than the analyst estimate of $0.43. Revenue for the quarter came in at $402.06 million versus the consensus estimate of $414.23 million.

GUIDANCE:

Integra LifeSciences sees Q4 2025 EPS of $0.79-$0.84, versus the consensus of $0.92. Integra LifeSciences sees Q4 2025 revenue of $420-440 million, versus the consensus of $456.2 million.

Integra LifeSciences sees FY2025 EPS of $2.19-$2.24, versus the consensus of $2.21. Integra LifeSciences sees FY2025 revenue of $1.62-1.64 billion, versus the consensus of $1.67 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Can JetBlue still avoid bankruptcy? Analysis says yes, but it won’t be easy
• One Stop Systems qualifies Gen5 expansion system for enterprise server platform
• Broadsoft (BSFT) PT Raised to $35 at Raymond James